The patent dispute on CRISPR between UC/Jennifer Doudna and The Broad/Feng Zhang has been the subject of major attention including in a recent piece on Stanford Center for Law & Biosciences Blog. There is a lot of confusion over this important CRISPR dispute so I turned to a patent expert for their take on this via an interview […]
Patent expert weighs in on CRISPR dispute between UC & Broad Read More »
CRISPR is the hottest new biotechnology and the top development of 2015 according to Science Magazine. What will the new year of 2016 bring on the CRISPR front? It’s clear there will be more meetings on CRISPR ethics and policy (heck, we are having one right here at UC Davis on May 26), but what
CRISPR predictions for New Year of 2016 Read More »
I’ve written a new book on human genetic modification. This is my second book as the first one was Stem Cells: An Insider’s Guide, which is currently the top stem cell book on Amazon. The new book is called GMO Sapiens: The Life-Changing Science of Designer Babies. You can pre-order it here at Amazon or over here at my publisher’s
GMO Sapiens book teaser: time to talk frankly on human genetic modification Read More »
Earlier this week I posted an interview with Steven Pinker on CRISPR, human germline modification, and bioethics. With only a few exceptions, I strongly disagree with Pinker’s philosophy in these areas and I knew going into the interview that his answers would likely go against my own views. I also expected the interview would anger
Why interview Steven Pinker on my blog if I strongly disagree with him? Read More »
CRISPR-Cas9 gene editing technology is red-hot right now and I’ve been doing interviews with various thought leaders on it, which today includes Steven Pinker. This technology has great power for research in the lab and there are hypothetical transformative clinical applications of CRISPR too. The latter efforts could include experimental attempts at reversal of disease-causing
Steven Pinker interview: case against bioethocrats & CRISPR germline ban Read More »
In my continuing series of conversations with thought leaders related to heritable human modification, today’s post is an interview with Natasha Vita-More, a pioneer in the transhumanism movement and Chairman of the Board of Directors of Humanity+ (H+), the global transhumanist organization. Where do you see transhumanism today? Has it changed over the years? What
Global transhumanism leader Natasha Vita-More on human germline modification Read More »
A decade ago I wrote an article in the journal Nature Biotechnology about the rise of a new gene editing technology called zinc finger nucleases (ZNF). It was one of those “drumbeat” discoveries: at the time, my sense was it would revolutionize how we deliver genes to cells and tissues, and profoundly change the way
Guest Post by Chris Scott–The Great CRISPR Controversy: What’s Next? Read More »
The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did
Was Fujifilm CDI acquisition a good move by the companies? Read More »
In the last few months the FDA has taken steps toward crystalizing regulatory oversight of stem cell and more broadly cell and tissue-based therapies. These steps come in the form of several draft guidances (see here, here, and here) . The Alliance for Regenerative Medicine (ARM) has responded to the draft guidance on Minimal Manipulation. For example, ARM has
ARM Asks FDA for Clarification on Draft Guidance on Minimal Manipulation Read More »
It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on
ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »